Panel Discussion: How to Characterise Rational Biomarkers/Endpoints?

Time: 3:30 pm
day: Day Two


  • Exploring biomarker selection – clinical presence of inflammation in the diseases
  • Utility in assessing disease progression and control of disease
  • What is a clinically meaningful benchmark of inflammasome inhibition?
  • What are the best tissue biomarkers of inflammasome inhibition?
  • What biomarkers and assays should be measured in a phase 1 or phase 2 trial to demonstrate inflammasome inhibition?
  • Overcoming the challenge of a lack of biomarkers to enable early intervention in disease
  • Validating assays in knockout models and testing assays in biological (plasma/serum) samples
  • Thoughts on future directions of this space and how companies can cover as many diseases as possible